News & Updates

Product Highlight - VPRIV

13 Dec 2022

Velaglucerase alfa, Powder for solution for infusion

Product Highlight - VPRIV

13 Dec 2022

Odevixibat improves pruritus, reduces bile acids in children with ALGS

13 Dec 2022 by

Treatment with odevixibat, a potent, selective IBAT* inhibitor, significantly improved pruritus and reduced serum bile acid levels in children with Alagille syndrome (ALGS), according to the ASSERT** trial presented at The Liver Meeting 2022.

Odevixibat improves pruritus, reduces bile acids in children with ALGS

13 Dec 2022

Hyperuricaemia modulates HDL-C-induced cardiovascular mortality in women

12 Dec 2022

Women with very high levels of high-density lipoprotein cholesterol (HDL-C) are at heightened risk of cardiovascular mortality, with the association following a J-shaped pattern, as reported in a study. Of note, the risk of cardiovascular mortality increases with concomitant hyperuricaemia.

Hyperuricaemia modulates HDL-C-induced cardiovascular mortality in women

12 Dec 2022

Low-dose polypill: Another step forward in hypertension management?

12 Dec 2022 by

A polypill comprising ultra-low doses of four antihypertensive drugs shows promise in reducing blood pressure (BP) levels compared with standard monotherapy, according to a small study presented at AHA 2022.

Low-dose polypill: Another step forward in hypertension management?

12 Dec 2022

Asians with MET exon 14 skipping NSCLC achieve durable response with tepotinib

12 Dec 2022 by

The MET inhibitor tepotinib demonstrates clinically meaningful antitumour activity, with durable efficacy and manageable safety profile in Asian nonsmall cell lung cancer (NSCLC) patients with MET mutations associated with exon 14 skipping, as shown in the subset analysis of the single-arm, phase II VISION study.

Asians with MET exon 14 skipping NSCLC achieve durable response with tepotinib

12 Dec 2022

Antipsychotic use lowers work disability risk

12 Dec 2022

Use of antipsychotics, particularly long-acting injectables, results in nearly 30‒50-percent reduced risk of work disability among individuals with first-episode nonaffective psychosis compared with nonuse, a study has shown. This benefit persists beyond 5 years after first diagnosis.

Antipsychotic use lowers work disability risk

12 Dec 2022

Durvalumab plus gemcitabine-cisplatin improves survival in advanced BTC

12 Dec 2022 by

First-line treatment with durvalumab plus gemcitabine and cisplatin (GC) leads to improved overall (OS) and progression-free survival (PFS) in advanced biliary tract cancer (BTC) across genomic variants, according to the results of the phase III study TOPAZ-1, presented at the ESMO Asia 2022.

Durvalumab plus gemcitabine-cisplatin improves survival in advanced BTC

12 Dec 2022

Which factors prevent or enable the safe handling of antineoplastic drugs?

12 Dec 2022

Several barriers and facilitators indicate the need to create work environments where safety is a priority for the handling of antineoplastic drugs, suggests a Canada study.

Which factors prevent or enable the safe handling of antineoplastic drugs?

12 Dec 2022

Resmetirom safe, effective in improving NASH fibrosis markers

12 Dec 2022 by

Treatment with the selective THR-β* agonist resmetirom for 52 weeks was well-tolerated and effective in reducing markers of NASH** fibrosis in a well-compensated Child-Pugh (CP)-A NASH population, a phase III trial has shown.

Resmetirom safe, effective in improving NASH fibrosis markers

12 Dec 2022

High-dose erythropoietin of little benefit to preemies with intraventricular haemorrhage

12 Dec 2022

The use of high-dose erythropoietin in the treatment of preterm infants with intraventricular haemorrhage (IVH) does not appear to produce improvements in neurological outcomes, according to a study.

High-dose erythropoietin of little benefit to preemies with intraventricular haemorrhage

12 Dec 2022

News & Updates

Filter by Specialty:

Specialty:

Product Highlight - VPRIV

Product Highlight - VPRIV

Odevixibat improves pruritus, reduces bile acids in children with ALGS

Odevixibat improves pruritus, reduces bile acids in children with ALGS

Hyperuricaemia modulates HDL-C-induced cardiovascular mortality in women

Hyperuricaemia modulates HDL-C-induced cardiovascular mortality in women

Low-dose polypill: Another step forward in hypertension management?

Low-dose polypill: Another step forward in hypertension management?

Asians with MET exon 14 skipping NSCLC achieve durable response with tepotinib

Asians with MET exon 14 skipping NSCLC achieve durable response with tepotinib

Antipsychotic use lowers work disability risk

Antipsychotic use lowers work disability risk

Durvalumab plus gemcitabine-cisplatin improves survival in advanced BTC

Durvalumab plus gemcitabine-cisplatin improves survival in advanced BTC

Which factors prevent or enable the safe handling of antineoplastic drugs?

Which factors prevent or enable the safe handling of antineoplastic drugs?

Resmetirom safe, effective in improving NASH fibrosis markers

Resmetirom safe, effective in improving NASH fibrosis markers

High-dose erythropoietin of little benefit to preemies with intraventricular haemorrhage

High-dose erythropoietin of little benefit to preemies with intraventricular haemorrhage